Drugs / RBM-001
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT06878170 Comparator | Sep 2024 → May 2025 overdue | COVID-19 | Rock BioMedical, Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RBM-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06878170 ↗ |
| Modality | Vaccine | “Low-dose study vaccine administered via intra-muscular injection.” NCT06878170 ↗ |
| Route | Intramuscular | “Low-dose study vaccine administered via intra-muscular injection.” NCT06878170 ↗ |